NASDAQ · SLXN
Healthcare · Biotechnology
$0.37
Up+$0.02 (+5.49%)
Updated Sep 1, 2026, 5:15 PM
SID Score
2.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
SLXN closed at $0.37 after 21 trading sessions, down 81.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $0.3674 | $0.3755 | $0.36 | $0.3697 | 153.86K |
| Aug 28, 2026 | $0.37 | $0.3759 | $0.353 | $0.3628 | 77.19K |
| Aug 27, 2026 | $0.3504 | $0.38 | $0.3501 | $0.3602 | 286.23K |
| Aug 26, 2026 | $0.374 | $0.374 | $0.3506 | $0.3549 | 228.41K |
| Aug 25, 2026 | $0.3601 | $0.3722 | $0.356 | $0.365 | 198.23K |
| Aug 24, 2026 | $0.377 | $0.389 | $0.3602 | $0.3676 | 275.86K |
| Aug 21, 2026 | $0.389 | $0.4056 | $0.377 | $0.3941 | 226.98K |
| Aug 20, 2026 | $0.4008 | $0.4099 | $0.3808 | $0.399 | 280.99K |
| Aug 19, 2026 | $0.4094 | $0.4141 | $0.3945 | $0.4132 | 306.82K |
| Aug 18, 2026 | $0.4074 | $0.4182 | $0.3871 | $0.4182 | 325.98K |
| Aug 17, 2026 | $0.413 | $0.422 | $0.3903 | $0.422 | 473.69K |
| Aug 14, 2026 | $0.4143 | $0.4202 | $0.373 | $0.4202 | 1.04M |
| Aug 13, 2026 | $0.4871 | $0.4871 | $0.411 | $0.46 | 1.13M |
| Aug 12, 2026 | $0.4387 | $0.49 | $0.43 | $0.4541 | 4.32M |
| Aug 11, 2026 | $1.49 | $1.50 | $1.0201 | $1.035 | 2.03M |
| Aug 10, 2026 | $1.81 | $1.8439 | $1.45 | $1.50 | 198.13K |
| Aug 7, 2026 | $1.78 | $1.95 | $1.78 | $1.87 | 80.6K |
| Aug 6, 2026 | $1.80 | $1.80 | $1.6798 | $1.79 | 33.09K |
| Aug 5, 2026 | $1.95 | $1.9504 | $1.73 | $1.80 | 36.11K |
| Aug 4, 2026 | $1.71 | $1.99 | $1.66 | $1.90 | 639.31K |
| Aug 3, 2026 | $1.88 | $2.00 | $1.81 | $1.95 | 39.37K |
The latest Smart Investors Daily articles mentioning SLXN.
SLXN research
Company profile and research snapshot.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 15, 2025 | Litchfield Hills | Buy | — |
| Mar 20, 2025 | Maxim Group | Buy | — |
| Nov 1, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per
Benzinga · Aug 12, 2026
US stocks rise, Nasdaq up 150 points. Dow up 0.13%, Nasdaq up 0.62%, S&P 500 up 0.35%. IT shares up 1.2%, healthcare down 0.9%. CPI rises 3.4%.
Benzinga · Aug 11, 2026
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Yahoo · Aug 4, 2026
Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancersNew preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines representing three distinct KRAS mutations (G12D, G12V, and G12C
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLXN.
